Browsing by Author Flaherty, Keith

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 18 of 18
Issue DateTitleAuthor(s)Citation
2013Age as a Prognostic Factor in Patients with Localized Melanoma and Regional MetastasesThompson, John; Atkins, Michael; Balch, Charles M; Cochran, Alistair; Coit, Daniel G.; Ding, Shouluan; Eggermont, Alexander; et al, Various; Flaherty, Keith; Gershenwald, Jeffrey E.; Gimotty, P A; Soong, Seng-Jaw; Central Clinical School: SurgeryAge as a Prognostic Factor in Patients with Localized Melanoma and Regional Metastases, Annals of Surgical Oncology, vol.20, 12, 2013,pp 3961-3968
2015Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase 1/2 clinical trialKefford, Richard (Rick); Long, Georgina; Menzies, Alexander Maxwel; Ashworth, Michelle T; et al, Various; Flaherty, Keith; Gonzalez, Rene; Hamid, Omid; Infante, Jeffrey; Kim, K B; Schuchter, Lynn; Swann, S; Weber, Jeffrey; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: MedicineCharacteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase 1/2 clinical trial, Annals of Oncology, vol.26, 2, 2015,pp 415-421
2014Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitorKefford, Richard (Rick); Long, Georgina; Cebon, Jonathan Simon; et al, Various; Flaherty, Keith; Hamid, Omid; Infante, Jeffrey; Johnson, Douglas B; Kim, Kevin; McWilliams, Robert; Schuchter, Lynn; Sharfman, William; Weber, Jeffrey; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer CentreCombined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor, Journal of Clinical Oncology, vol.32, 33, 2014,pp 3697-3704
2016Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trialsKefford, Richard (Rick); Long, Georgina; Carver, Jennifer; Casey, Michelle; Flaherty, Keith; Gagnon, Robert; Goodman, Vicki; Haney, Patricia; Hauschild, Axel; Hwu, Patrick; Legos, Jeffrey J.; Martin, Anne-Marie; Mazumdar, Jolly; O'Hagan, Anne; Santiago-Walker, Ademi; Schadendorf, D; Western Clinical School: Westmead Institute for Medical Res; Central Clinical School: The Sydney Cancer CentreCorrelation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials, Clinical Cancer Research, vol.22, 3, 2016,pp 567-574
2017Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trialLong, Georgina; Arance, Ana; Chiarion-Sileni, Vanna; Davies, Michael; Del Vecchio, M; Flaherty, Keith; Grob, Jean-Jacques; Hogg, David; Huang, Yingjie; Lebbe, Celeste; Lesimple, Thierry; Márquez-Rodas, Ivan; Meyer, Nicolas; Mookerjee, Bijoyesh P; Mortier, Laurent; Moschos, S; Robert, Caroline; Saiag, Philippe; Thomas, Luc; Zhang, Ying; Northern Clinical School: MedicineDabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial, The Lancet Oncology, vol.18, 7, 2017,pp 863-873
2016Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trialsLong, Georgina; Davies, Michael; Flaherty, Keith; Grob, Jean-Jacques; Lane, Stephen; Legenne, Philippe; Mak, Carmen; Nathan, Paul; Ribas, Antoni; Robert, Caroline; Schadendorf, D; Northern Clinical School: MedicineFactors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials, The Lancet Oncology, vol.17, 12, 2016,pp 1743-1754
2012FUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the “Melanoma Research: a bridge from Naples to the World. Napoli, December 5th–6 th 2011”Kefford, Richard (Rick); Ascierto, Paolo; Curti, Brendan; et al, Various; Faries, Mark B.; Ferrone, Soldano; Flaherty, Keith; Fox, Bernard; Gajewski, Thomas; Gershenwald, Jeffrey E.; Gogas, Helen; Grimaldi, Antonio; Western Clinical School: Westmead Millennium InstituteFUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the “Melanoma Research: a bridge from Naples to the World. Napoli, December 5th–6 th 2011”, Journal of Translational Medicine, vol.10, May, 2012,pp 1-17
2014Genetic Alterations and Personalized Medicine in Melanoma: Progress and Future ProspectsScolyer, Richard; Thompson, John; Flaherty, Keith; Griewank, Klaus; Murali, Rajmohan; Schadendorf, Dirk; Central Clinical School: Pathology; Central Clinical School: SurgeryGenetic Alterations and Personalized Medicine in Melanoma: Progress and Future Prospects, Journal of the National Cancer Institute, vol.106, 2, 2014,pp 1-17
2012Improved Survival with MEK Inhibition in BRAF-Mutated MelanomaHersey, Peter; Demidov, Lev; Drummer, Reinhard; et al, Various; Flaherty, Keith; Garbe, Claus; Hassel, Jessica; Milhem, Mohammed; Mohr, P; Nathan, Paul; Robert, Caroline; Rutkowski, Piotr; Northern Clinical School: SurgeryImproved Survival with MEK Inhibition in BRAF-Mutated Melanoma, New England Journal of Medicine, vol.367, 2, 2012,pp 107-114
2012New challenges in endpoints for drug development in advanced melanomaHersey, Peter; Flaherty, Keith; Gogas, Helen; Kirkwood, John M; Middleton, Mark; Ribas, Antoni; Sondak, Vernon; Northern Clinical School: SurgeryNew challenges in endpoints for drug development in advanced melanoma, Clinical Cancer Research, vol.18, 2, 2012,pp 336-341
2014Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitorsKefford, Richard (Rick); Long, Georgina; Menzies, Alexander Maxwel; Ackerman, Allison; Atkins, Michael; Flaherty, Keith; Gunturi, Anasuya; Hodi, F. Stephen; Ibrahim, Nageatte; Klein, Oliver; Lawrence, Donald; McDermott, David; Sullivan, Ryan; Wang, Wei; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: MedicineOutcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors, Cancer, vol.120, 11, 2014,pp 1695-1701
2013Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic MelanomaHersey, Peter; Long, Georgina; et al, Various; Flaherty, Keith; Gonzalez, Rene; Hutson, Thomas; Kim, Kevin; McArthur, Grant A.; Moschos, Stergios; Pavlick, Anna C.; Schuchter, Lynn; Trunzer, Kerstin; Weber, Jeffrey; Northern Clinical School: Surgery; Central Clinical School: The Sydney Cancer CentrePharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma, Journal of Clinical Oncology, vol.31, 14, 2013,pp 1767-1774
2011Prognostic Significance of Mitotic Rate in Localized Primary Cutaneous Melanoma: An Analysis of Patients in the Multi-Institutional American Joint Committee on Cancer Melanoma Staging DatabaseThompson, John; Balch, Charles M.; Byrd, David; Cascinelli, N T; Cochran, Alistrair; Coit, Daniel G.; Ding, Shouluan; Eggermont, Alexander; Flaherty, Keith; Gershenwald, Jeffrey E.; Gimotty, P A; Johnson, Marcella; Johnson, Timothy; Leong, Stanley; McMasters, Kelly; Mihm, Martin Jr; Morton, Donald; Ross, Merrick I; Sondak, Vernon; Soong, Seng-Jaw; Central Clinical School: SurgeryPrognostic Significance of Mitotic Rate in Localized Primary Cutaneous Melanoma: An Analysis of Patients in the Multi-Institutional American Joint Committee on Cancer Melanoma Staging Database, Journal of Clinical Oncology, vol.29, 16, 2011,pp 2199-2205
2016The state of melanoma: challenges and opportunitiesLong, Georgina; Bastian, Boris; Curiel-Lewandrowski, Clara; Davies, Michael; et al, Various; Fisher, David Erich; Flaherty, Keith; Herlyn, Meenhard; Merlino, Glenn T.; Wargo, Jennifer A.; Weber, Michael J.; Central Clinical School: The Sydney Cancer CentreThe state of melanoma: challenges and opportunities, Pigment Cell & Melanoma Research, vol.29, 4, 2016,pp 404-416
2014Surrogate endpoints for overall survival in metastatic melanoma: A meta-analysis of randomised controlled trialsKefford, Richard (Rick); Long, Georgina; Ascierto, Paolo; Dummer, R; Eggermont, Alexander; Flaherty, Keith; Hauschild, A; Hennig, Michael; Kirkwood, John; Lee, Sandra J; Lorigan, Paul; Mackensen, Andreas; McArthur, Grant A.; O'Day, Steven; Patel, Poulam; Robert, Caroline; Schadendorf, D; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer CentreSurrogate endpoints for overall survival in metastatic melanoma: A meta-analysis of randomised controlled trials, The Lancet Oncology, vol.15, 3, 2014,pp 297-304
2012Survival in BRAF V600-mutant advanced melanoma treated with vemurafenibHersey, Peter; Kefford, Richard (Rick); et al, Various; Flaherty, Keith; Gonzalez, Rene; Hutson, Thomas; Kim, Kevin; McArthur, Grant A.; Moschos, Stergios; Pavlick, Anna C.; Schuchter, Lynn; Sosman, Jeffrey; Weber, Jeffrey; Northern Clinical School: Surgery; Western Clinical School: Westmead Millennium InstituteSurvival in BRAF V600-mutant advanced melanoma treated with vemurafenib, New England Journal of Medicine, vol.366, 8, 2012,pp 707-714
2016Survival of patients with advanced metastatic melanoma: The impact of novel therapiesLong, Georgina; Ascierto, Paolo; et al, Various; Flaherty, Keith; Grob, Jean-Jacques; Hauschild, Axel; Larkin, James; Lorigan, Paul; McArthur, Grant A.; Rohmel, Joachim; Ugurel, Selma; Northern Clinical School: MedicineSurvival of patients with advanced metastatic melanoma: The impact of novel therapies, European Journal of Cancer, vol.53, N/A, 2016,pp 125-134
2017Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017Long, Georgina; Ascierto, Paolo; et al, Various; Flaherty, Keith; Grob, Jean-Jacques; Hauschild, Axel; Larkin, James; Lorigan, Paul; McArthur, Grant A.; Rohmel, Joachim; Ugurel, Selma; Northern Clinical School: MedicineSurvival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017, European Journal of Cancer, vol.83, N/A, 2017,pp 247-257